Opendata, web and dolomites

MATADOR

MAmmary chemoresistant Tumor deAth by Directed cell ORientation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "MATADOR" data sheet

The following table provides information about the project.

Coordinator
COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES 

Organization address
address: RUE LEBLANC 25
city: PARIS 15
postcode: 75015
website: www.cea.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 149˙645 €
 EC max contribution 149˙645 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES FR (PARIS 15) coordinator 149˙645.00

Map

 Project objective

Breast cancer is the most common cancer in women worldwide, with nearly 1.7 million new cases diagnosed in 2012. Fortunately, the availability of diagnosis tools to detect mammary neoplastic tissues, as well as transcriptomic biomarkers helping for prognosis, and the diversity of treatment options for primary tumors allows a 90% 5-year survival rate. However the metastatic grade of breast cancer is still not curable. Advances from basic research in the last decade outline the epithelial-to-mesenchymal transition (EMT) as a key program of molecular events triggering metastatic dissemination [Nieto MA, Cell, 2016]. Impairing the EMT process appears as a very seductive way to cure breast carcinoma cancer. Based on preliminary results obtained from “SPICY” ERC Frontier Research Starting Grant, in which we successfully develop an assay dedicated to characterize the EMT state of breast carcinoma cells [Thery M, EP 2180042 A1, 2008 ; Burute M, Dev. Cell, 2016], MATADOR is an ERC proof-of-concept project which proposes a genuine innovative strategy to develop marketable cell based assays allowing the discovery of new drugs efficiently curing mammary tumors, and create a CRO-type biotechnology company exploiting the pre-existing and newly created intellectual property: including marketable assays and therapeutics defined in MATADOR.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MATADOR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MATADOR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

DISINTEGRATION (2019)

The Mass Politics of Disintegration

Read More  

HyperBio (2019)

Vis-NIR Hyperspectral imaging for biomaterial quality control

Read More